Literature DB >> 19561097

Lethal effect of CD3-specific antibody in mice deficient in TGF-beta1 by uncontrolled flu-like syndrome.

Sylvain Perruche1, Pin Zhang, Takashi Maruyama, Jeffrey A Bluestone, Philippe Saas, WanJun Chen.   

Abstract

CD3-specific Ab therapy results in a transient, self-limiting, cytokine-associated, flu-like syndrome in experimental animals and in patients, but the underlying mechanism for this spontaneous resolution remains elusive. By using an in vivo model of CD3-specific Ab-induced flu-like syndrome, we show in this paper that a single injection of sublethal dose of the Ab killed all TGF-beta1(-/-) mice. The death of TGF-beta1(-/-) mice was associated with occurrence of this uncontrolled flu-like syndrome, as demonstrated by a sustained storm of systemic inflammatory TNF and IFN-gamma cytokines. We present evidence that deficiency of professional phagocytes to produce TGF-beta1 after apoptotic T cell clearance may be responsible, together with hypersensitivity of T cells to both activation and apoptosis, for the uncontrolled inflammation. These findings indicate a key role for TGF-beta1 and phagocytes in protecting the recipients from lethal inflammation and resolving the flu-like syndrome after CD3-specific Ab treatment. The study may also provide a novel molecular mechanism explaining the early death in TGF-beta1(-/-) mice.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19561097      PMCID: PMC2842991          DOI: 10.4049/jimmunol.0804076

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  52 in total

Review 1.  Transforming growth factor-beta. Multiple actions and potential clinical applications.

Authors:  M B Sporn; A B Roberts
Journal:  JAMA       Date:  1989-08-18       Impact factor: 56.272

2.  Effects of in vivo administration of anti-CD3 monoclonal antibody on T cell function in mice. II. In vivo activation of T cells.

Authors:  R Hirsch; R E Gress; D H Pluznik; M Eckhaus; J A Bluestone
Journal:  J Immunol       Date:  1989-02-01       Impact factor: 5.422

3.  Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-gamma [corrected].

Authors:  L Chatenoud; C Ferran; A Reuter; C Legendre; Y Gevaert; H Kreis; P Franchimont; J F Bach
Journal:  N Engl J Med       Date:  1989-05-25       Impact factor: 91.245

4.  Deactivation of macrophages by transforming growth factor-beta.

Authors:  S Tsunawaki; M Sporn; A Ding; C Nathan
Journal:  Nature       Date:  1988-07-21       Impact factor: 49.962

5.  Cytokine-related syndrome following injection of anti-CD3 monoclonal antibody: further evidence for transient in vivo T cell activation.

Authors:  C Ferran; K Sheehan; M Dy; R Schreiber; S Merite; P Landais; L H Noel; G Grau; J Bluestone; J F Bach
Journal:  Eur J Immunol       Date:  1990-03       Impact factor: 5.532

6.  Hypothermia and hypoglycemia induced by anti-CD3 monoclonal antibody in mice: role of tumor necrosis factor.

Authors:  M Alegre; P Vandenabeele; V Flamand; M Moser; O Leo; D Abramowicz; J Urbain; W Fiers; M Goldman
Journal:  Eur J Immunol       Date:  1990-03       Impact factor: 5.532

7.  TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes.

Authors:  Mériam Belghith; Jeffrey A Bluestone; Samia Barriot; Jérôme Mégret; Jean-François Bach; Lucienne Chatenoud
Journal:  Nat Med       Date:  2003-08-24       Impact factor: 53.440

8.  Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients.

Authors:  D Abramowicz; L Schandene; M Goldman; A Crusiaux; P Vereerstraeten; L De Pauw; J Wybran; P Kinnaert; E Dupont; C Toussaint
Journal:  Transplantation       Date:  1989-04       Impact factor: 4.939

9.  Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3.

Authors:  WanJun Chen; Wenwen Jin; Neil Hardegen; Ke-Jian Lei; Li Li; Nancy Marinos; George McGrady; Sharon M Wahl
Journal:  J Exp Med       Date:  2003-12-15       Impact factor: 14.307

10.  Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor beta, interleukin 4, and prostaglandin E expression in the brain.

Authors:  S J Khoury; W W Hancock; H L Weiner
Journal:  J Exp Med       Date:  1992-11-01       Impact factor: 14.307

View more
  5 in total

1.  A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens.

Authors:  Gregory L Moore; Cristina Bautista; Erik Pong; Duc-Hanh T Nguyen; Jonathan Jacinto; Araz Eivazi; Umesh S Muchhal; Sher Karki; Seung Y Chu; Greg A Lazar
Journal:  MAbs       Date:  2011-11-01       Impact factor: 5.857

Review 2.  The safety and side effects of monoclonal antibodies.

Authors:  Trevor T Hansel; Harald Kropshofer; Thomas Singer; Jane A Mitchell; Andrew J T George
Journal:  Nat Rev Drug Discov       Date:  2010-03-22       Impact factor: 84.694

3.  Pathological features of new animal models for primary biliary cirrhosis.

Authors:  Koichi Tsuneyama; Yuki Moritoki; Kentaro Kikuchi; Yasuni Nakanuma
Journal:  Int J Hepatol       Date:  2011-07-06

4.  Control of the differentiation of regulatory T cells and T(H)17 cells by the DNA-binding inhibitor Id3.

Authors:  Takashi Maruyama; Jun Li; Jose P Vaque; Joanne E Konkel; Weifeng Wang; Baojun Zhang; Pin Zhang; Brian F Zamarron; Dongyang Yu; Yuntao Wu; Yuan Zhuang; J Silvio Gutkind; WanJun Chen
Journal:  Nat Immunol       Date:  2010-12-05       Impact factor: 25.606

5. 

Authors:  Shimpei Kasagi; Dandan Wang; Pin Zhang; Peter Zanvit; Hua Chen; Dunfang Zhang; Jia Li; Li Che; Takashi Maruyama; Hiroko Nakatsukasa; Ruiqing Wu; Wenwen Jin; Lingyun Sun; WanJun Chen
Journal:  EBioMedicine       Date:  2019-05-13       Impact factor: 8.143

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.